'Rikst Biotechnology' listed in the US to begin virtual asset accumulation

Son Min

Summary

The Nasdaq-listed company, "Rikst Biotechnology," has announced its approval of a virtual asset accumulation strategy.
The board of directors decided to invest up to 25% of the company's reserves in virtual assets.
The CEO views virtual assets as a hedge against existing reserve assets and a means to create shareholder value, expressing trust in their long-term potential.

Rikst Biotechnology Holdings, a biopharmaceutical company listed on Nasdaq, plans to begin accumulating virtual assets (cryptocurrencies).

According to GlobeNewswire on the 13th (local time), Rikst Biotechnology announced in a press release, "The board of directors has approved a virtual asset accumulation strategy," and stated, "We will invest up to 25% of our corporate reserves in virtual assets."

Geordan Pursglove (CEO) said, "Virtual assets are a hedge against traditional reserve assets and a means to generate value for shareholders," adding, "We believe in the long-term potential of virtual assets."